How it works
Get started by filling out the online enrollment application to find out if you are eligible for assistance.
NiceRx verifies your eligibility for medication assistance and notifies you if you are pre-qualified. The pharmaceutical company provides your medication for free, and you only pay our service fee.
We will request documents to be submitted by you and your healthcare provider that are required by the pharmaceutical company to complete your enrollment.
Once approved, the pharmaceutical company typically ships a 90-day supply of medication to your home or healthcare provider’s address. Final acceptance is determined by the pharmaceutical company.
Your monthly Saphnelo cost savings if eligible
If you are eligible for the Saphnelo patient assistance program you can receive your medication for free. Our monthly service fee of $49 per medication covers the cost of our services in applying for the program and requesting your ongoing refills on your behalf. If you obtain your Saphnelo through NiceRx, you will only pay $49 a month regardless of the retail price of your medication.
Am I eligible for the Saphnelo patient assistance program?
You could receive your Saphnelo without paying the full retail price if you meet the eligibility criteria for assistance. The eligibility requirements are set by the pharmaceutical companies that are providing assistance programs. At NiceRx, we review each application individually, although the main factors considered by most programs are:
- I am a permanent, legal resident of the United States or Puerto Rico
- I am uninsured or my insurance doesn’t cover my medication
- I meet certain income eligibility requirements
How do I apply for Saphnelo patient assistance?
We do everything that we can to take the hassle and stress out of applying for patient assistance programs. Simply start by filling in our enrollment application. We will ask for details about your healthcare provider, your insurance, and your household income. This information is required by the pharmaceutical companies you are applying to for assistance. We may also be able to help you access patient assistance for other medications that you have been prescribed, so be sure to tell us about any medications you are taking as well as Saphnelo.
NiceRx will review the information you have provided, and if we determine that you may be eligible for assistance, we will seek to enroll you in the Saphnelo patient assistance program. We will handle the enrollment process for you by working with your healthcare provider and preparing all the required paperwork for your doctor to sign. We will also request your Saphnelo medication refills on your behalf for up to 1 year once you are enrolled in the program.
Is NiceRx a Saphnelo coupons provider?
At NiceRx, we help eligible individuals access the Saphnelo patient assistance program. This means that we are not a Saphnelo coupon, a Saphnelo discount card, or a Saphnelo copay card provider. We do not offer any medication trial offers or free Saphnelo samples.
Can NiceRx help me get Saphnelo if I have insurance?
We may be able to help you if you have insurance, including if your insurance company will not pay for your Saphnelo medication, or you have a high copay or coinsurance responsibility. We may even be able to assist if you do not have insurance. Please fill in our enrollment application to find out more.
How much does Saphnelo cost without insurance?
Saphnelo costs without insurance will vary depending on YYYY and the retailer you buy it from. As a guide, Saphnelo intravenous solution (300 mg/2 mL) will typically cost around $4,800 for 2 milliliters. If you obtain your medication through NiceRx, you will pay a flat monthly rate of $49 per medication regardless of its retail price.
How much does Saphnelo cost with insurance?
The copay of Saphnelo will vary in line with the specific terms of your healthcare plan. For further details about what you may need to pay, your insurance provider or pharmacist will be able to calculate the copay costs with your current insurance.
What is Saphnelo?
Saphnelo (anifrolumab-fnia) is a fully human monoclonal antibody and a type I interferon (type I IFN) receptor antagonist manufactured by AstraZeneca. It has FDA approval (U.S. Food and Drug Administration) for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy.
Limitations of Use – The efficacy of Saphnelo has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus.
What doses of Saphnelo are available?
Saphnelo is available in injection form, in the following doses: 300 mg/2 mL (150 mg/mL) in a single-dose vial.
The recommended dose is 300 mg as an intravenous infusion over a 30-minute period every 4 weeks.
Please see full prescribing information, including patient information. Always speak with your healthcare provider for medical advice or about any changes to your dose so they can monitor and evaluate your condition.
Saphnelo active ingredients
Saphnelo contains the active ingredient anifrolumab-fnia.
Clinical trials for Saphnelo (TULIP-1, TULIP-2, and MUSE) were randomized, double-blinded, placebo-controlled trials in patients with moderate to severe SLE who were receiving standard therapy. Standard therapy included at least one of the following: OCS, antimalarials, and immunosuppressants (methotrexate, azathioprine, or mycophenolate mofetil).
The TULIP (Treatment of Uncontrolled Lupus via the Interferon Pathway) Phase III program included two trials, TULIP-1 and TULIP-2, that evaluated the efficacy and safety of Saphnelo versus placebo. TULIP-2 showed superiority versus placebo with both arms receiving standard therapy. TULIP-2 assessed the ability of Saphnelo to reduce disease activity, as measured by the BILAG-Based Composite Lupus Assessment (BICLA) scale.
In TULIP-1, 457 eligible patients were randomized (1:2:2) and received a fixed-dose intravenous infusion of 150mg Saphnelo, 300mg Saphnelo or placebo every four weeks, in addition to standard therapy. The trial did not meet its primary endpoint based on the SLE Responder Index 4 (SRI4) composite measure.
The MUSE trial showed improvement versus placebo across multiple efficacy endpoints with both arms receiving standard therapy.
In SLE, along with the pivotal TULIP Phase III program, Saphnelo continues to be evaluated in a long-term extension Phase III trial and a Phase III trial assessing subcutaneous delivery. Also, AstraZeneca is exploring the potential of Saphnelo in a variety of diseases where type I IFN plays a key role, including lupus nephritis, cutaneous lupus erythematosus, and myositis.
Saphnelo side effects
The most common side effects of Saphnelo in clinical trials include:
- Infusion-related reactions
In rare instances, Saphnelo can cause more serious side effects. These can include:
- Serious infections – upper respiratory infections, bronchitis, cough, shingles (herpes zoster). Anifrolumab-fnia can lower the ability of your immune system to fight infections leading to hospitalization or death
- Hypersensitivity reactions including anaphylaxis
Your doctor will assess the benefits of using Saphnelo against your risk of side effects. Patients are encouraged to report negative side effects or adverse reactions of Saphnelo to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Saphnelo drug interactions
Saphnelo can interact with other medications. These include:
- Biologic therapies
This list is not exhaustive and other prescription drugs may interact with Saphnelo.
You should not use Saphnelo if you:
- Have a history of anaphylaxis with anifrolumab-fnia
- Are allergic to any of the other ingredients in Saphnelo
Talk to your doctor before using Saphnelo if you:
- Are taking any of the medications that could interact with Saphnelo
- Are pregnant or are planning to become pregnant – a pregnancy exposure registry monitors pregnancy outcomes in women
- Are breastfeeding or are planning to breastfeed
- Have recently had a vaccination – avoid the use of live or live-attenuated vaccines
Saphnelo is the trademark brand name for anifrolumab-fnia manufactured by AstraZeneca. A generic version of anifrolumab-fnia is not available. Generic drugs are generally cheaper than brand-name drugs, but you can still find Saphnelo savings through NiceRx.
The content on this website is intended for information purposes only. It does not constitute medical advice. The information on this website should not be relied upon and is not a substitute for professional medical advice. You should always speak to your doctor regarding the risks and benefits of any treatment.